Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development
Reference number: GID-TA10467
Expected publication date: TBC
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant.
For information, the company has advised it has paused its effort to pursue a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.